The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.

Lauren Carcas; Jessica Macintyre; Jaime R. Merchan; Peter Joel Hosein; Ikechukwu Immanuel Akunyili; Maria Restrepo; Monica T. Garcia; Lorraine Portelance; Danny Sleeman; Joe U Levi; Caio Max S. Rocha Lima

doi:10.1200/jco.2015.33.3_suppl.460

The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.

Lauren Carcas, Jessica Macintyre, Jaime R. Merchan, Peter Joel Hosein, Ikechukwu Immanuel Akunyili, Maria Restrepo, Monica T. Garcia, Lorraine Portelance, Danny Sleeman, Joe U Levi, Caio Max S. Rocha Lima

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	33
DOIs	https://doi.org/10.1200/jco.2015.33.3_suppl.460
State	Published - Jan 20 2015

Disciplines

Medicine and Health Sciences
Pathology

Access to Document

10.1200/jco.2015.33.3_suppl.460License: Unspecified

Cite this

Carcas, L., Macintyre, J., Merchan, J. R., Hosein, P. J., Akunyili, I. I., Restrepo, M., Garcia, M. T., Portelance, L., Sleeman, D., Levi, J. U., & Lima, C. M. S. R. (2015). The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx. Journal of Clinical Oncology, 33. https://doi.org/10.1200/jco.2015.33.3_suppl.460

The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx. / Carcas, Lauren; Macintyre, Jessica; Merchan, Jaime R. et al.
In: Journal of Clinical Oncology, Vol. 33, 20.01.2015.

Research output: Contribution to journal › Article › peer-review

Carcas, L, Macintyre, J, Merchan, JR, Hosein, PJ, Akunyili, II, Restrepo, M, Garcia, MT, Portelance, L, Sleeman, D, Levi, JU & Lima, CMSR 2015, 'The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.', Journal of Clinical Oncology, vol. 33. https://doi.org/10.1200/jco.2015.33.3_suppl.460

Carcas L, Macintyre J, Merchan JR, Hosein PJ, Akunyili II, Restrepo M et al. The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx. Journal of Clinical Oncology. 2015 Jan 20;33. doi: 10.1200/jco.2015.33.3_suppl.460

@article{ff50c65ed6d54f5dbac13a052635f45b,

title = "The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.",

author = "Lauren Carcas and Jessica Macintyre and Merchan, {Jaime R.} and Hosein, {Peter Joel} and Akunyili, {Ikechukwu Immanuel} and Maria Restrepo and Garcia, {Monica T.} and Lorraine Portelance and Danny Sleeman and Levi, {Joe U} and Lima, {Caio Max S. Rocha}",

note = "460 Background: No validated biomarkers exist to direct treatment decisions in PDAC. Decisions regarding tx choices are based on age, organ function, and performance status. Defining predictors of efficacy to F (alone or in combination) or G (alone or in combination) in PDAC are urgently needed.",

year = "2015",

month = jan,

day = "20",

doi = "10.1200/jco.2015.33.3_suppl.460",

language = "American English",

volume = "33",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.

AU - Carcas, Lauren

AU - Macintyre, Jessica

AU - Merchan, Jaime R.

AU - Hosein, Peter Joel

AU - Akunyili, Ikechukwu Immanuel

AU - Restrepo, Maria

AU - Garcia, Monica T.

AU - Portelance, Lorraine

AU - Sleeman, Danny

AU - Levi, Joe U

AU - Lima, Caio Max S. Rocha

N1 - 460 Background: No validated biomarkers exist to direct treatment decisions in PDAC. Decisions regarding tx choices are based on age, organ function, and performance status. Defining predictors of efficacy to F (alone or in combination) or G (alone or in combination) in PDAC are urgently needed.

PY - 2015/1/20

Y1 - 2015/1/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.460

U2 - 10.1200/jco.2015.33.3_suppl.460

DO - 10.1200/jco.2015.33.3_suppl.460

M3 - Article

VL - 33

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

The Value of Tissue Protein Expression as a Predictor of Efficacy for First- or Second-line Therapy (tx) in Metastatic Ductal Pancreas Cancer (PDAC) in Patients (pts) Receiving either Gemcitabine (G)-based tx or 5FU (F)-based tx.

Disciplines

Access to Document

Other files and links

Cite this